Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention

E. W. Gerner, F. L. Meyskens, S. Goldschmid, Michael P Lance, D. Pelot

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Polyamine metabolic genes are downstream targets of several genes commonly mutated in colon adenomas and cancers. Inhibitors of ornithine decarboxylase, such as difluoromethylornithine (DFMO), and agents that stimulate polyamine acetylation and export, such as non-steroidal anti-inflammatory drugs (NSAIDS), act at least additively to arrest growth in human cell models and suppress intestinal carcinogenesis in mice. These preclinical studies provided the rationale for colon cancer prevention trials in humans. A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colorectal tissue polyamine and prostaglandin E2 contents and overall toxicity to participants. Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. Seventy percent of participants will have completed the three years of treatment in December 2006.

Original languageEnglish (US)
Pages (from-to)189-195
Number of pages7
JournalAmino Acids
Volume33
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

Eflornithine
Chemoprevention
Polyamines
Metabolism
Colonic Neoplasms
Sulindac
Clinical Trials
Genes
Placebos
Acetylation
Non-Steroidal Anti-Inflammatory Agents
Polyps
Dinoprostone
Adenoma
Toxicity
Colon
Carcinogenesis
Anti-Inflammatory Agents
Cells
Tissue

Keywords

  • Chemoprevention
  • Clinical trials
  • Colon cancer
  • Difluoromethylornithine
  • Nonsteroidal anti-inflammatory drugs
  • Polyamines

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry
  • Endocrinology

Cite this

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. / Gerner, E. W.; Meyskens, F. L.; Goldschmid, S.; Lance, Michael P; Pelot, D.

In: Amino Acids, Vol. 33, No. 2, 08.2007, p. 189-195.

Research output: Contribution to journalArticle

Gerner, E. W. ; Meyskens, F. L. ; Goldschmid, S. ; Lance, Michael P ; Pelot, D. / Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. In: Amino Acids. 2007 ; Vol. 33, No. 2. pp. 189-195.
@article{30f2fa930b234b75985002731b686a53,
title = "Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention",
abstract = "Polyamine metabolic genes are downstream targets of several genes commonly mutated in colon adenomas and cancers. Inhibitors of ornithine decarboxylase, such as difluoromethylornithine (DFMO), and agents that stimulate polyamine acetylation and export, such as non-steroidal anti-inflammatory drugs (NSAIDS), act at least additively to arrest growth in human cell models and suppress intestinal carcinogenesis in mice. These preclinical studies provided the rationale for colon cancer prevention trials in humans. A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colorectal tissue polyamine and prostaglandin E2 contents and overall toxicity to participants. Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. Seventy percent of participants will have completed the three years of treatment in December 2006.",
keywords = "Chemoprevention, Clinical trials, Colon cancer, Difluoromethylornithine, Nonsteroidal anti-inflammatory drugs, Polyamines",
author = "Gerner, {E. W.} and Meyskens, {F. L.} and S. Goldschmid and Lance, {Michael P} and D. Pelot",
year = "2007",
month = "8",
doi = "10.1007/s00726-007-0515-2",
language = "English (US)",
volume = "33",
pages = "189--195",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",
number = "2",

}

TY - JOUR

T1 - Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention

AU - Gerner, E. W.

AU - Meyskens, F. L.

AU - Goldschmid, S.

AU - Lance, Michael P

AU - Pelot, D.

PY - 2007/8

Y1 - 2007/8

N2 - Polyamine metabolic genes are downstream targets of several genes commonly mutated in colon adenomas and cancers. Inhibitors of ornithine decarboxylase, such as difluoromethylornithine (DFMO), and agents that stimulate polyamine acetylation and export, such as non-steroidal anti-inflammatory drugs (NSAIDS), act at least additively to arrest growth in human cell models and suppress intestinal carcinogenesis in mice. These preclinical studies provided the rationale for colon cancer prevention trials in humans. A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colorectal tissue polyamine and prostaglandin E2 contents and overall toxicity to participants. Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. Seventy percent of participants will have completed the three years of treatment in December 2006.

AB - Polyamine metabolic genes are downstream targets of several genes commonly mutated in colon adenomas and cancers. Inhibitors of ornithine decarboxylase, such as difluoromethylornithine (DFMO), and agents that stimulate polyamine acetylation and export, such as non-steroidal anti-inflammatory drugs (NSAIDS), act at least additively to arrest growth in human cell models and suppress intestinal carcinogenesis in mice. These preclinical studies provided the rationale for colon cancer prevention trials in humans. A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colorectal tissue polyamine and prostaglandin E2 contents and overall toxicity to participants. Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. Seventy percent of participants will have completed the three years of treatment in December 2006.

KW - Chemoprevention

KW - Clinical trials

KW - Colon cancer

KW - Difluoromethylornithine

KW - Nonsteroidal anti-inflammatory drugs

KW - Polyamines

UR - http://www.scopus.com/inward/record.url?scp=34547678673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547678673&partnerID=8YFLogxK

U2 - 10.1007/s00726-007-0515-2

DO - 10.1007/s00726-007-0515-2

M3 - Article

VL - 33

SP - 189

EP - 195

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 2

ER -